Trial Profile
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Inhalative Doses (20 µg, 50 µg, 100 µg, 200 µg and 400 µg) of BEA 2180 BR for 21 Days in Healthy Male Volunteers (Double-blind, Randomised, Placebo Controlled [at Each Dose Level] Study)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 08 Oct 2014
Price :
$35
*
At a glance
- Drugs BEA 2180-BR (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Adverse reactions; Therapeutic Use
- Sponsors Boehringer Ingelheim
- 08 Oct 2014 New trial record